<DOC>
	<DOCNO>NCT00493454</DOCNO>
	<brief_summary>Primary Objective : - Overall Response Rate ( ORR ) . Secondary Objectives : - The Duration Response ( DR ) Time Treatment Progression ( TTP ) patient responder . - Complete Responses ( CR ) /Complete Responses unconfirmed ( CRu ) , Partial Responses ( PR ) . - Time next anticancer therapy ( TTNT ) .</brief_summary>
	<brief_title>Ibritumomab Tiuxetan Treatment Non-Follicular CD20+ Indolent Lymphomas</brief_title>
	<detailed_description>^90 Y Ibritumomab tiuxetan rituximab design attach lymphoma cell , cause die . Before start treatment study , call `` screening test . '' These test help doctor decide eligible take part study . You physical exam . Your blood ( 2 3 teaspoon ) urine collect routine test . You chest x-ray computerized tomography ( CT ) scan neck , chest , abdomen , pelvis . You bone marrow aspirate biopsy perform . To collect bone marrow aspirate biopsy , area hip chest bone numb anesthetic , small amount bone marrow bone withdrawn large needle . Women able child must negative blood pregnancy test . The study doctor first make sure disease spread much severe require immediate treatment chemotherapy begin treatment study . If find eligible take part study , give Benadryl ( diphenhydramine ) vein , give Tylenol ( acetaminophen ) mouth dose rituximab . This do help decrease risk develop side effect rituximab . You receive 1 dose rituximab vein 6 8 hour Day 1 treatment . After treatment rituximab , give radioactive antibody , ^111 In Ibritumomab tiuxetan ( radioactive agent bind rituximab help image exam ) , vein 10 minute . This researcher use special camera see drug body . You image perform ( special camera ) Day 1 either Day 2 Day 3 . On Day 8 , receive second dose rituximab . This follow dose ^90 Y Ibritumomab tiuxetan give vein 10 minute . This complete treatment . If experience intolerable side effect study , may remove study . The study doctor offer treatment option . For follow-up , blood ( 2 tablespoon ) draw week first 3 month , every 3 month 1 year , every 4 month second year . At visit , may also CT scan , x-ray , bone marrow biopsy aspirate perform , need . This investigational study . ^90 Y Ibritumomab tiuxetan rituximab approve FDA treatment indolent B-cell lymphoma . Up 35 patient take part multicenter study . Up 15 enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . No anticancer therapy three week ( six week Rituximab , nitrosourea Mitomycin C ) prior study initiation , fully recover acute toxicity associate prior surgery , radiation treatment , chemotherapy , immunotherapy . 2 . Previously treat patient histology refractory/relapsed indolent lymphoma include : ( ) Extranodal marginal lymphoma MALT type ; ( b ) Nodal Marginal zone Bcell lymphoma ( +/ monocytoid cell ) ; ( c ) Splenic marginal Bcell lymphoma ( +/ villous lymphocyte ) . 3 . Signed informed consent 4 . Age &gt; /= 18 year 5 . Expected survival &gt; /= 3 month 6 . Prestudy Zubrod performance status 0 , 1 , 2 7 . Acceptable hematologic status within two week prior patient registration , include : ( ) Absolute neutrophil count ( [ segment neutrophil + band ] * total white blood count ( WBC ) ) &gt; /= 1,500/mm^3 ; ( b ) Platelet count &gt; /= 100,000/mm^3 . 8 . Female patient pregnant lactate 9 . Men woman reproductive potential following accept birth control method ( determine treat physician ) 10 . Patients previously Phase II drug longterm toxicity expect , patient drug eight week significant post treatment toxicity observe 11 . Patients determine &lt; 25 % bone marrow involvement lymphoma within six week registration ( define measurement bone marrow aspirate biopsy ) ( This criterion must strictly meet adequate patient safety . ) 12 . Patient least one lesion measure &gt; /= 2 cm single dimension . 1 . Prior myeloablative therapy autologous bone marrow transplantation ( ABMT ) peripheral blood stem cell ( PBSC ) rescue . 2 . Platelet count &lt; 100,000 cells/mm^3 . 3 . Presence hypocellular bone marrow . 4 . Patients history fail stem cell collection . 5 . Prior radioimmunotherapy 6 . Presence Central Nervous System ( CNS ) lymphoma 7 . Patients HIV . 8 . Patients pleural effusion 9 . Patients abnormal liver function : total bilirubin &gt; 2.0 mg/dL 10 . Patients abnormal renal function : serum creatinine &gt; 2.0 mg/dL 11 . Patients receive prior external beam radiation therapy &gt; 25 % active bone marrow ( involved field regional ) 12 . Patients receive shortacting growth factor support ( Leukine , Neupogen , Procrit ) within 2 week prior treatment longacting growthfactor support ( Aranesp ) , Neulasta ) within 4 week prior treatment . 13 . Serious nonmalignant disease infection , opinion investigator and/or sponsor , would compromise protocol objective 14 . Major surgery , diagnostic surgery , within four week 15 . Evidence transformation late biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Indolent Lymphoma</keyword>
	<keyword>Extranodal Marginal</keyword>
	<keyword>Nodal Marginal Zone</keyword>
	<keyword>Splenic Marginal</keyword>
	<keyword>MALT Type</keyword>
	<keyword>Zevalin</keyword>
	<keyword>Ibritumomab Tiuxetan</keyword>
	<keyword>Rituximab</keyword>
</DOC>